

<i>Highly Specialised Technologies (HST)</i>	<i>Date of HST Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication Yes OR No</i>	<i>Reason provided if "No"</i>
2018-19			
HST1 - Eculizumab for treating atypical haemolytic uraemic syndrome	28/01/2015	No	Not applicable to CWFT - Condition not treated at CWFT
HST2 - Elosulfase alfa for treating mucopolysaccharidosis type Iva	16/12/2015	No	Not applicable to CWFT - Condition not treated at CWFT
HST3 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene	20/07/2016	No	Not applicable to CWFT - Condition not treated at CWFT
HST4 - Migalastat for treating Fabry disease	22/02/2017	No	Not applicable to CWFT - Condition not treated at CWFT
HST5 - Eliglustat for treating type 1 Gaucher disease	28/06/2017	No	Not applicable to CWFT - Condition not treated at CWFT
HST6 - Asfotase alfa for treating paediatric-onset hypophosphatasia	02/08/2017	No	Not applicable to CWFT - Condition not treated at CWFT
HST7 - Strimvelis for treating adenosine deaminase deficiency-severe combined immunodeficiency	07/02/2018	No	Not applicable to CWFT - Condition not treated at CWFT
HST8 - Burosumab for treating X-linked hypophosphataemia in children and young people	10/10/2018	No	Not applicable to CWFT - Condition not treated at CWFT